Halozyme

Covestor Ltd boosted its holdings in Halozyme Therapeutics, Inc. () by 223.5% in the second quarter, according to its most recent Form 13F filing with the SEC.

Finally, Dimensional Fund Advisors LP lifted its stake in Halozyme Therapeutics by 13.7% during the third quarter.

Equities analysts expect that Halozyme Therapeutics, Inc. will post 3.71 EPS for the current fiscal year.

Halozyme also views its Enhanze drug delivery technology as complementary to Evotec’s biologics manufacturing platform.

Halozyme Therapeutics () last issued its quarterly earnings results on Tuesday, August 6th.

Halozyme Therapeutics () last posted its quarterly earnings results on Tuesday, May 7th.

On average, analysts predict that Halozyme Therapeutics, Inc. will post 3.66 earnings per share for the current fiscal year.

Whittier Trust Co. bought a new position in Halozyme Therapeutics during the first quarter worth about $27,000.

Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success.

Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, November 6th.

Halozyme TherapeuticsSupernus PharmaceuticalsEnanta Pharmaceuticals) are among the top 5 highly rated stocks within the group.

In terms of top and bottom line numbers, Halozyme Therapeutics has posted four quarters of increasing earnings growth.

We reiterate our Overweight rating and 12-month price target of $27/share of Halozyme.